Compare AQN & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AQN | ALKS |
|---|---|---|
| Founded | 1988 | 1987 |
| Country | Canada | Ireland |
| Employees | 3786 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.5B |
| IPO Year | N/A | 2012 |
| Metric | AQN | ALKS |
|---|---|---|
| Price | $6.16 | $29.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 14 |
| Target Price | $6.57 | ★ $43.29 |
| AVG Volume (30 Days) | ★ 4.4M | 2.0M |
| Earning Date | 03-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.19% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.43 |
| Revenue | N/A | ★ $1,475,899,000.00 |
| Revenue This Year | $3.34 | $24.26 |
| Revenue Next Year | $4.77 | $4.63 |
| P/E Ratio | ★ N/A | $20.93 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.45 | $25.17 |
| 52 Week High | $7.11 | $36.32 |
| Indicator | AQN | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 35.97 | 51.21 |
| Support Level | $5.99 | $27.48 |
| Resistance Level | $6.13 | $30.36 |
| Average True Range (ATR) | 0.15 | 0.92 |
| MACD | -0.03 | 0.34 |
| Stochastic Oscillator | 3.81 | 80.21 |
Algonquin Power & Utilities Corp is a Canada-based diversified international generation, transmission, and distribution company. The company's operations are organized across two business units: the Regulated Services Group, which owns and operates a portfolio of regulated electric, water distribution, and wastewater collection, and natural gas utility systems and transmission operations in the United States, Canada, Bermuda, and Chile; and the Hydro Group, which consists of hydroelectric-generating facilities located in Canada. It generates the majority of its revenue from the Regulated Services Group segment.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.